EMA accepts GSK’s bepirovirsen for chronic hepatitis B review
#EMA #GSK #bepirovirsen #chronic hepatitis B #regulatory review #antisense oligonucleotide #hepatitis B virus #treatment
📌 Key Takeaways
- EMA accepted GSK's bepirovirsen for regulatory review for chronic hepatitis B treatment.
- Bepirovirsen is an investigational antisense oligonucleotide therapy targeting hepatitis B virus.
- The review could lead to a new therapeutic option for a chronic viral infection affecting millions globally.
- This marks a significant step in GSK's hepatitis B pipeline and potential market authorization in Europe.
🏷️ Themes
Regulatory Review, Hepatitis B Treatment
Entity Intersection Graph
No entity connections available yet for this article.